FluoxetineThird Party Manufacturing in India

Fluoxetine works by selectively inhibiting the reuptake of serotonin (5-hydroxytryptamine or 5-HT) at the presynaptic neuronal membrane in the central nervous system. By blocking the serotonin transporter protein, fluoxetine increases the concentration of serotonin in the synaptic cleft, thereby enhancing serotonergic neurotransmission. This effect occurs through negative allosteric modulation of the serotonin receptor complex, which prevents the recycling of serotonin back into the presynaptic neuron. With chronic administration, the sustained elevation of synaptic serotonin leads to desensitisation and downregulation of postsynaptic 5-HT receptors, which is believed to be the mechanism underlying the antidepressant response. Unlike tricyclic antidepressants, fluoxetine has minimal affinity for adrenergic, histaminergic, and muscarinic receptors, which explains its more favourable side effect profile. The drug also exhibits mild inhibitory effects on the reuptake of norepinephrine and dopamine at higher concentrations. Additionally, fluoxetine may suppress the expression of pro-inflammatory cytokines such as interleukin-6, contributing to its immunomodulatory effects. Its active metabolite, norfluoxetine, has a half-life of several days, allowing for sustained therapeutic coverage even after missed doses.

Therapeutic Uses

Fluoxetine is prescribed for the treatment of:

• Major Depressive Disorder (MDD): Fluoxetine is one of the most widely prescribed first-line antidepressants for moderate to severe depression. It improves mood, restores interest in daily activities, and alleviates associated symptoms such as sleep disturbances and appetite changes.

• Obsessive-Compulsive Disorder (OCD): Fluoxetine is approved for the treatment of OCD in adults and children. It helps reduce the frequency and intensity of obsessive thoughts and compulsive behaviours.

• Bulimia Nervosa: Fluoxetine is indicated for moderate to severe bulimia nervosa, where it reduces binge-eating episodes and purging behaviours.

• Panic Disorder: With or without agoraphobia, fluoxetine is effective in reducing the frequency and severity of panic attacks.

• Premenstrual Dysphoric Disorder (PMDD): Fluoxetine is approved for the treatment of PMDD, typically administered continuously or intermittently during the luteal phase.

• Treatment-Resistant Depression: In combination with olanzapine, fluoxetine is indicated for treatment-resistant depression and bipolar I depression.

Why Manufacturers Choose Fluoxetine

Fluoxetine is a high-volume antidepressant molecule with sustained global demand. As a WHO Essential Medicine, it is manufactured extensively in India for both domestic PCD franchise distribution and export to regulated markets. The molecule is well-characterised with established manufacturing processes, making it ideal for WHO-GMP certified facilities. Indian manufacturers produce fluoxetine as 20mg tablets and capsules, catering to a broad patient population. The expiry of patent protection has led to widespread generic adoption, creating steady demand from institutional buyers and government health programmes. Its stable API supply chain and cost-effective synthesis make fluoxetine one of the most commercially viable molecules for third party manufacturing in India, with consistent year-round demand for PCD franchise and export orders.